Conectus
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5 Rue Schiller, Strasbourg, Grand-Est, 6...Phone Number
+33 368411260Website
www.conectus.frRevenue
$5.6 MillionIndustry
About Conectus
Is Conectus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Conectus had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Conectus has new funding data
Product Launch: Get notified when Conectus launches new products
Check out if Conectus is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Conectus, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Conectus has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Conectus recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Conectus
Recommended Actions
Find VP level buyers at Conectus
Find more new buyers
Company Profile Activity
Activity Insights
Conectus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Conectus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Conectus.
Conectus Tech Stack
A closer look at the technologies used by Conectus
Conectus News & Media
SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients
PARIS--(BUSINESS WIRE)--SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and license option agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK lSATT[1] Conectus and Find Therapeutics Sign Licensing Agreement to Develop a Promising New Therapy for Multiple Sclerosis and other demyelinating diseases
New potential therapy to promote the regeneration of damaged myelin in Multiple Sclerosis (MS) and Optic Neuritis (ON) 3 million people are living with MS worldwide – 1 million living in North America MS is a major public health issue with a global drugs market estimated at $28 billion in...Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an exclusive, worldwide license agreement with SATT Conectus for the development and commercialization of a gene therapy candidate for the treatment of Fragile X syndrome. Under the terms of the agreement, Lysogene will be responsible for the preclinical and clinical development, manu
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Conectus
SATT Conectus specializes in technology transfer and public-private research collaborations in Alsace. The company connects businesses with researchers to co-develop innovative projects, access cutting-edge technological platforms, and create startups. Since its inception in 2012, Conectus has facilitated numerous technology transfers and partnersh... Read More